# OnCo record paper-kindler-lancet-oncol (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-kindler-lancet-oncol/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-kindler-lancet-oncol" ;
  schema:name "Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trial"@en ;
  schema:description "Paper cited by one trial page, one treatment page and one idea page, indexed on Europe PMC as PubMed record 35358455 and published in The Lancet Oncology; the citing pages link this DOI, which is how the record was matched."@en ;
  schema:url <https://onco.cc/key-papers/paper-kindler-lancet-oncol/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(22)00061-4>, <https://pubmed.ncbi.nlm.nih.gov/35358455/>, <https://europepmc.org/article/MED/35358455> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(22)00061-4> ;
  schema:datePublished "2022"^^xsd:gYear ;
  schema:author "Kindler HL, Novello S, Bearz A, et al." ;
  onco:related <https://onco.cc/drugs/anetumab-ravtansine/>, <https://onco.cc/ideas/idea-adc-for-mesothelioma/> ;
  onco:trials <https://onco.cc/trials/anetumab-vs-vinorelbine-mpm/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .